NDA 207925 · Vertex Pharms INC
Kalydeco
Ivacaftor · Oral · Cystic Fibrosis Transmembrane Conductance Regulator Potentiator
Breakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Mar 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Mar 17, 2015
Approved uses
10
Original approval plus efficacy supplements
Registered trials
136
60 Phase 3, 11 recruiting
FAERS reports
7,984
5,947 serious, 327 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 23, 2026.
KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients aged 1 month and older who have at least one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data [see Clinical Pharmacology (12.1) and Clinical Studies (14) ] . If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients aged 1 month and older who have at least one mutation in the CFTR gene that is responsive to ivacaftor based on clinical and/or in vitro assay data. ( 12.1 , 14 ) If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. ( 1 )
Mechanism: Ivacaftor is a potentiator of the CFTR protein. The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. Ivacaftor facilitates increased chloride transport by potentiating the channel open probability (or gating) of CFTR protein located at the cell surface. The overall level of ivacaftor-mediated CFTR chloride transport is dependent on the amount of CFTR protein at the cell surface and how responsive a particular mutant CFTR protein is to ivacaftor potentiation. CFTR Chloride Transport Assay in Fischer Rat Thyroid (FRT) cells expressing mutant CFTR...
Therapeutic areas: Respiratory
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 22, 2025 Supplement 19 · Efficacy · priority review OrphanLetterLabel
- May 3, 2023 Supplement 16 · Efficacy · priority review OrphanLabelLetter
- Dec 21, 2020 Supplement 13 · Efficacy · priority review OrphanLetterLabel
- Sep 24, 2020 Supplement 11 · Efficacy · priority review OrphanLetterLabel
- Apr 29, 2019 Supplement 8 · Efficacy · priority review OrphanLabelLetter
- Aug 15, 2018 Supplement 7 · Efficacy · priority review OrphanLetterLabel
- Jul 31, 2017 Supplement 5 · Efficacy · priority review OrphanLabelLetter
- May 17, 2017 Supplement 1 · Efficacy · priority review OrphanLabelLetter
- Feb 8, 2017 Supplement 3 · Efficacy OrphanLetterLabel
- Mar 17, 2015 Original approval · Type 3 - New Dosage Form · priority review Breakthrough therapyOrphanSummary ReviewLetterLabel
5 products under this application
- KALYDECO · IVACAFTOR 13.4MG/PACKET · GRANULE, ORAL · Prescription
- KALYDECO · IVACAFTOR 25MG/PACKET · GRANULE, ORAL · Prescription
- KALYDECO · IVACAFTOR 50MG/PACKET · GRANULE, ORAL · Prescription
- KALYDECO · IVACAFTOR 5.8MG/PACKET · GRANULE, ORAL · Prescription
- KALYDECO · IVACAFTOR 75MG/PACKET · GRANULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ivacaftor" as an intervention, any sponsor and status, largest first.
- A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic FibrosisPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT01931839 · 1,164 participants · Start Oct 2013 · Primary completion Apr 2016
Drug: Lumacaftor Plus Ivacaftor Combination; Ivacaftor · For: Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Sites: Birmingham, Alabama; Anchorage, Alaska; Tucson, Arizona · 166 sites in all
- A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR MutationPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT02565914 · 1,131 participants · Start Aug 2015 · Primary completion May 2019
Drug: TEZ/IVA; IVA · For: Cystic Fibrosis
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 154 sites in all
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05076149 · 597 participants · Start Oct 27, 2021 · Primary completion May 18, 2023
Drug: VX-121/TEZ/D-IVA; ELX/TEZ/IVA and 4 more · For: Cystic Fibrosis
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 170 sites in all
- A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR MutationPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT01807949 · 563 participants · Start Apr 2013 · Primary completion Apr 2014
Drug: Placebo; Lumacaftor Plus Ivacaftor Combination and 1 more · For: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Sites: Oakland, California; Sacramento, California; Aurora, Colorado · 82 sites in all
- A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR MutationPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT01807923 · 559 participants · Start May 2013 · Primary completion Apr 2014
Drug: Lumacaftor Plus Ivacaftor Combination; Ivacaftor and 1 more · For: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Sites: Birmingham, Alabama; Anchorage, Alaska; Tucson, Arizona · 89 sites in all
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With IvacaftorPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT02347657 · 510 participants · Start Jan 2015 · Primary completion Jan 20, 2017
Drug: VX-661 Plus Ivacaftor Combination; Ivacaftor and 2 more · For: Cystic Fibrosis
Sites: Little Rock, Arkansas; Long Beach, California; Denver, Colorado · 74 sites in all
- A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination TherapyPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT03525574 · 507 participants · Start Oct 9, 2018 · Primary completion Jan 9, 2023
Drug: ELX/TEZ/IVA; IVA · For: Cystic Fibrosis
Sites: Tucson, Arizona; Little Rock, Arkansas; Long Beach, California · 110 sites in all
- A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination TherapyPivotal-lookingTerminated
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT03447262 · 484 participants · Start Jul 13, 2018 · Primary completion Sep 9, 2020
Drug: VX-659/TEZ/IVA; IVA · For: Cystic Fibrosis
Sites: Birmingham, Alabama; Palo Alto, California; Aurora, Colorado · 100 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hospitalisation1,384
- infective pulmonary exacerbation of cystic fibrosis611
- pneumonia271
- infection257
- lower respiratory tract infection255
- malaise255
- death229
- cough225
- cystic fibrosis220
- headache197
- nasopharyngitis171
- influenza162
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 174 |
| 2013 | 129 |
| 2014 | 383 |
| 2015 | 523 |
| 2016 | 271 |
| 2017 | 403 |
| 2018 | 558 |
| 2019 | 1,037 |
| 2020 | 896 |
| 2021 | 593 |
| 2022 | 651 |
| 2023 | 598 |
| 2024 | 750 |
| 2025 | 695 |
| 2026 | 323 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Kalydeco (IVacaftor)
2024 spending
$28.7M
Beneficiaries
105
1,101 claims
Per beneficiary
$273,600
$465.28 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $37,664,939 |
| 2021 | $25,900,494 |
| 2022 | $25,486,737 |
| 2023 | $25,099,036 |
| 2024 | $28,727,989 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
Middleton PG, Mall MA, Devínek P, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Multicenter Study
- VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Keating D, Marigowda G, Burr L, et al. · N Engl J Med 2018 · Clinical Trial, Phase II, Multicenter Study
- Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.
Barry PJ, Mall MA, Álvarez A, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM, McKone EF, Downey DG, et al. · Lancet 2019 · Clinical Trial, Phase III, Randomized Controlled Trial
- Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.
Keating C, Yonker LM, Vermeulen F, et al. · Lancet Respir Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.
Uluer AZ, MacGregor G, Azevedo P, et al. · Lancet Respir Med 2023 · Randomized Controlled Trial, Clinical Trial, Phase II
Sponsor: Vertex Pharmaceuticals
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.